Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in new merchant acquisitions [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service [2]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable [2]. - The lawsuit contends that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - Allegations state that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it is linked to fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second patient death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death related to Elevidys was reported on July 17, 2025, causing the stock to fall more than 40% on July 18, 2025 [5].

Core Viewpoint - Molina Healthcare, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price declines [1][2][3]. Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [2]. - The finalized second-quarter results on July 23, 2025, showed adjusted earnings per diluted share of $5.48, which missed both analyst consensus estimates and prior company guidance [3]. - The earnings shortfall was attributed to elevated medical cost pressures, including increased utilization of behavioral health, pharmacy, and inpatient/outpatient services [3]. Stock Price Reaction - Following the preliminary earnings announcement on July 7, 2025, Molina's stock price fell by $6.97, or approximately 2.9%, closing at $232.61 per share [2]. - After the finalized second-quarter results on July 23, 2025, the stock price dropped by $32.03, or approximately 16.8%, closing at $158.22 per share [4].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - JMP Securities has lowered its price target on Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [2] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 per share on July 28, 2025 [3]

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in acquiring new merchants [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service, leading to a significant slowdown in Clover's growth [2]. - The lawsuit asserts that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for violations of federal securities laws, specifically related to misleading statements about oil production operations [1][4]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased Sable's securities during the secondary public offering on May 21, 2025, and within the class period from May 19, 2025, to June 3, 2025 [2]. - The Schall Law Firm is representing the investors and encourages those who suffered losses to contact them before September 26, 2025 [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Sable made false and misleading statements regarding the restart of oil production off the California coast, while in reality, operations were still shut down [4]. - These misleading public statements caused investors to suffer damages once the truth about Sable's operations was revealed [4].

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response to their biologics license application for RP1 [1][2][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. - The company announced positive results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application to the FDA based on these results [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Replimune securities [2]. - The complaint alleges that the IGNYTE Phase 1/2 trial design was inadequate to produce reliable results, despite the company promoting its outcomes [4]. Group 3: Stock Performance - Following the FDA's Complete Response Letter on July 22, 2025, which indicated that the IGNYTE trial was not considered adequate for demonstrating effectiveness, Replimune's stock price fell by more than 75% [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration of its business with 3M's Food Safety Division and the financial implications of this merger [1][3][4]. Company Overview - Neogen Corporation specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Class Action Details - The class action lawsuit is titled "Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation" and allows investors who purchased Neogen common stock between January 5, 2023, and June 3, 2025, to seek appointment as lead plaintiff by September 16, 2025 [1][7]. - The lawsuit alleges that Neogen's executives made false statements about the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3][4]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - In the third quarter of 2025, Neogen reported a loss of $11 million, a significant increase from a $2 million loss the previous year, with revenue declining by 3.4% to $221 million due to integration issues [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further decline in stock price by over 17% [6].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for alleged violations of federal securities laws, focusing on misleading statements and operational issues related to its Payeezy and Clover platforms [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks damages for investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, inclusive [2]. - Allegations include that Fiserv forced Payeezy merchants to transition to Clover due to cost-related issues, leading to inflated revenue growth figures for Clover [3]. - It is claimed that many former Payeezy merchants abandoned Clover for competitors due to high pricing and poor customer service, resulting in a deceleration of Clover's growth [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Fiserv have until September 22, 2025, to request appointment as lead plaintiff in the class action [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - Harrow reported Q1 2025 revenue of $47.8 million, which was below the consensus estimate of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [3]